The goal of this retrospective study is to see whether patients with familial partial type 2 lipodystrophy, who are at high cardiovascular risk present a higher volume of visceral epicardial adipose tissue than other patients without familial partial lipodystrophy who were assessed for their cardiovascular risk using coronary artery calcification scoring between 2016 and 2024.

Coronary artery calcification and clinical cardiovascular risk scoring are insufficient for patients with Familial Partial Lipodystrophy Part 2 (FPLD2), who often develop cardiovascular events before 40 and are insulin resistant. Epicardial adipose tissue volume could be a new, earlier marker of interest for these patients related to inflammation and atherosclerosis. The investigators retrospectively included high cardiovascular risk patients from 2016 to 2023 who had benefited from coronary artery calcification and clinical risk scoring at the University Hospital of La Réunion with Familial Partial Lipodystrophy Type 2 or controls and paired them for age, sex and body mass index. Epicardial adipose tissue volume was measured on the same tododensitometry as the CAC scoring, using a semi, automated technique that had been validated with deep learning at the Univeristy Hospital of Aix-Marseille.

Inclusion Criteria:

Patients who received a check-up for hypercholesterolemia, obesity or diabetes including a CT scan to measure the coronary calcium score at the CHU de La Réunion between 2016 and 2023

Exclusion Criteria:

None

Patients who received a check-up for hypercholesterolemia, obesity or diabetes including a CT scan to measure the coronary calcium score at the CHU de La Réunion between 2016 and 2023